Which component is part of the requirements for a new drug application?

The correct choice is clinical data because it is a fundamental requirement for any new drug application (NDA) submitted to the FDA. Clinical data provides evidence of the drug's safety and efficacy based on studies conducted in humans. This data is collected through various phases of clinical trials, which assess how the drug interacts with the body and its pharmacological effects.

In contrast, while other aspects mentioned could be relevant in different contexts, they are not mandatory components for the approval process of a new drug application. Current market trends, advertising plans, and patient feedback may provide insight into the market acceptance or commercial strategies post-approval but do not directly influence the regulatory decision regarding a drug's approval, which primarily relies on robust clinical evidence.